Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maridebart Cafraglutide (AMG 133) SC Presentations in Overweight or Obesity
NCT07226778Phase 1Completed
- Sponsor
- Amgen
- Start
- Oct 2025
- Primary completion
- May 2026
- Modality
- Peptides, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of maridebart cafraglutide in obesity (2 arms), sponsored by Amgen. Primary endpoints: Area Under the Plasma Concentration Time Curve from Time Zero to Infinity, Area Under the Plasma Concentration Time Curve from Time Zero to Time of Last Quantifiable Concentration and 1 more. Started Oct 2025; status: completed.
02
Drugs
maridebart cafraglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07226778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07226778.